Start Time: 08:30 January 1, 0000 9:18 AM ET Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q4 2020 Earnings Conference Call March 16, 2021, 08:30 AM ET Company Participants Patrick McEnany - Co-Founder, Chairman and CEO Alicia Grande - VP, CFO and Treasurer Steven Miller - COO and Chief Scientific Officer Jeff Del Carmen - Chief Commercial Officer Conference Call Participants Joe Catanzaro - Piper Sandler Charles Duncan - Cantor Fitzgerald Les Sulewski - Truist Securities Scott Henry - ROTH Capital Operator ...

Table of Contents Title of Each ClassTicker SymbolName of Exchange on Which Registered Common Stock, par value $0.001 per share CPRX NASDAQ Capital Market Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [Mark One] ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 0 ...

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q3 2020 Earnings Conference Call November 10, 2020 8:30 AM ET Company Participants Alicia Grande - Chief Financial Officer Patrick McEnany - Chairman & Chief Executive Officer Steven Miller - Chief Operating Officer & Chief Scientific Officer Jeffrey Del Carmen - Chief Commercial Officer Conference Call Participants Joe Catanzaro - Piper Sandler Charles Duncan - Cantor Fitzgerald Scott Henry - Roth Capital Operator Greetings and welcome to Catalyst Pharmaceutical ...

Table of Contents Title of Each ClassTicker SymbolName of Exchange on Which Registered Common Stock, par value $0.001 per share CPRX NASDAQ Capital Market Emerging growth company ☐ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [Mark One] ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2020 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission ...

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q2 2020 Earnings Conference Call August 11, 2020 8:30 AM ET Company Participants Alicia Grande - Chief Financial Officer Patrick McEnany - Chairman and Chief Executive Officer Jeffrey Del Carmen - Chief Commercial Officer Steven Miller - Chief Operating Officer and Chief Scientific Officer Gary Ingenito - Chief Medical Regulatory Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Leland Gershell - Oppenheimer Operator Hello and welcome to the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of Each ClassTicker SymbolName of Exchange on Which Registered Common Stock, par value $0.001 per share CPRX NASDAQ Capital Market Emerging growth company ☐ FORM 10-Q [Mark One] ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2020 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-33057 CAT ...

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q1 2020 Earnings Conference Call May 12, 2020 8:30 AM ET Company Participants Alicia Grande - Chief Financial Officer Patrick McEnany - Chairman and Chief Executive Officer Dan Brennan - Chief Commercial Officer Steven Miller - Chief Operating Officer and Chief Scientific Officer Conference Call Participants Joe Catanzaro - Piper Sandler Charles Duncan - Cantor Fitzgerald Leland Gershell - Oppenheimer Scott Henry - ROTH Capital Operator Greetings and welcome to ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [Mark One] ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2020 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-33057 355 Alhambra Circle Suite 1250 Coral Gables, Florida 33134 (Address of principal executive offices) (Zip Code) (IRS Employer Identification No.) Re ...

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q4 2019 Earnings Conference Call March 17, 2020 8:30 AM ET Company Participants Alicia Grande - Chief Financial Officer Patrick McEnany - Chairman and Chief Executive Officer Daniel Brennan - Chief Commercial Officer Steven Miller - Chief Operating Officer and Chief Scientific Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald & Co. Joseph Catanzaro - Piper Sandler Leland Gershell - Oppenheimer & Co. Inc. Scott Henry - ROTH Capital Partners, ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [Mark One] ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-33057 CATALYST PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 76-0837053 (State of jurisdiction of incorporation ...